Tacrolimus - Generic Drug Details

What are the generic drug sources for tacrolimus and what is the scope of patent protection?

Tacrolimus is the generic ingredient in five branded drugs marketed by Astellas, Chengdu, Accord Hlthcare, Ajenat Pharms, Alkem Labs Ltd, Biocon Pharma, Concord Biotech Ltd, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hangzhou Zhongmei, Heritage Pharma Avet, Mylan, Panacea, Sandoz, Strides Pharma, Hospira, Nexus, Leo Pharma As, Encube, Fougera Pharms Inc, and Veloxis Pharms Inc, and is included in twenty-six NDAs. There are ten patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tacrolimus has thirty patent family members in sixteen countries.

There are twenty drug master file entries for tacrolimus. Thirty-four suppliers are listed for this compound.

Summary for tacrolimus

International Patents:	30
US Patents:	10
Tradenames:	5
Applicants:	21
NDAs:	26
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	34
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	1,392
Drug Prices:	Drug price trends for tacrolimus
Drug Sales Revenues:	Drug sales revenues for tacrolimus
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tacrolimus
What excipients (inactive ingredients) are in tacrolimus?	tacrolimus excipients list
DailyMed Link:	tacrolimus at DailyMed

See drug prices for tacrolimus

See drug sales revenues for tacrolimus

Recent Clinical Trials for tacrolimus

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Veloxis Pharmaceuticals	PHASE2
Shalamar Institute of Health Sciences	PHASE3
Fred Hutchinson Cancer Center	PHASE2

See all tacrolimus clinical trials

Pharmacology for tacrolimus

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors

Medical Subject Heading (MeSH) Categories for tacrolimus

Calcineurin Inhibitors

Immunosuppressive Agents

Anatomical Therapeutic Chemical (ATC) Classes for tacrolimus

D11AH	Agents for dermatitis, excluding corticosteroids
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

L04AD	Calcineurin inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for TACROLIMUS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENVARSUS XR	Extended-release Tablets	tacrolimus	0.75 mg, 1 mg and 4 mg	206406	1	2022-03-31
ASTAGRAF XL	Extended-release Capsules	tacrolimus	0.5 mg, 1 mg, and 5 mg	204096	1	2013-09-24
PROTOPIC	Ointment	tacrolimus	0.03%	050777	1	2010-11-22
PROTOPIC	Ointment	tacrolimus	0.10%	050777	1	2010-09-09

US Patents and Regulatory Information for tacrolimus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Concord Biotech Ltd	TACROLIMUS	tacrolimus	CAPSULE;ORAL	213112-001	Nov 10, 2020	AB	RX	No	No
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015		RX	Yes	No			Y
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015		RX	Yes	Yes			Y
Mylan	TACROLIMUS	tacrolimus	CAPSULE;ORAL	090596-002	Sep 17, 2010	AB	RX	No	No
Alkem Labs Ltd	TACROLIMUS	tacrolimus	CAPSULE;ORAL	203740-003	Nov 12, 2020	AB	RX	No	No
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015		RX	Yes	Yes
Astellas	PROGRAF	tacrolimus	CAPSULE;ORAL	050708-002	Apr 8, 1994	AB	RX	Yes	Yes

Expired US Patents for tacrolimus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015
Astellas	ASTAGRAF XL	tacrolimus	CAPSULE, EXTENDED RELEASE;ORAL	204096-003	Jul 19, 2013
Leo Pharma As	PROTOPIC	tacrolimus	OINTMENT;TOPICAL	050777-001	Dec 8, 2000
Astellas	ASTAGRAF XL	tacrolimus	CAPSULE, EXTENDED RELEASE;ORAL	204096-003	Jul 19, 2013
Astellas	ASTAGRAF XL	tacrolimus	CAPSULE, EXTENDED RELEASE;ORAL	204096-001	Jul 19, 2013
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015

EU/EMA Drug Approvals for tacrolimus

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Modigraf	tacrolimus	EMEA/H/C/000954Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.	Authorised	no	no	no	2009-05-15
Astellas Pharma Europe BV	Advagraf	tacrolimus	EMEA/H/C/000712Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Authorised	no	no	no	2007-04-23
Chiesi Farmaceutici S.p.A.	Envarsus	tacrolimus	EMEA/H/C/002655Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Authorised	no	no	no	2014-07-18
LEO Pharma A/S	Protopic	tacrolimus	EMEA/H/C/000374Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).	Authorised	no	no	no	2002-02-27
Teva B.V.	Tacforius	tacrolimus	EMEA/H/C/004435Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Authorised	yes	no	no	2017-12-08
Astellas Pharma GmbH	Protopy	tacrolimus	EMEA/H/C/000375Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).	Withdrawn	no	no	no	2002-02-28

International Patents for tacrolimus

Country	Patent Number	Title	Estimated Expiration
Portugal	2575769
Denmark	2167033
Canada	2688381
Lithuania	2575769
Eurasian Patent Organization	201390412	СТАБИЛИЗИРОВАННАЯ КОМПОЗИЦИЯ ТАКРОЛИМУСА
Hungary	E033011
World Intellectual Property Organization (WIPO)	2010005980

Market Dynamics and Financial Trajectory for Tacrolimus

Last updated: January 15, 2026

Summary

Tacrolimus, a potent immunosuppressant primarily utilized in organ transplant recipients and autoimmune disorders, has experienced a complex market evolution driven by patent statuses, regulatory policies, manufacturing developments, and competitive pressures. Despite its long-standing presence since its FDA approval in 1994, tacrolimus continues to generate significant revenue streams, with the global market projected to grow amidst emerging biosimilar entrants, evolving treatment protocols, and regional adoption patterns. This analysis delineates the key market drivers, revenue forecasts, challenges, and strategic considerations essential for stakeholders navigating the tacrolimus landscape.

---

What Are the Market Drivers for Tacrolimus?

Driver	Details	Implications
High Clinical Demand	Tacrolimus remains the gold-standard immunosuppressant for solid organ transplants—kidney, liver, heart—due to proven efficacy in preventing rejection.	Sustained demand in transplantation medicine sustains revenue streams.
Regulatory Approvals & Guidelines	Global acceptance of tacrolimus for transplant immunosuppression; inclusion in treatment guidelines by bodies such as KDIGO (Kidney Disease: Improving Global Outcomes).	Reinforces market stability and physician prescribing behaviors.
Patent Expirations & Biosimilars	The originator brand, Prograf (AbbVie), faced patent expiry in key markets (e.g., US in 2017). Biosimilar entrants like Astellas’ ACS-14 and Hikma’s tacrolimus have entered markets post-patent expiry.	Price competition and market share redistribution due to biosimilars.
Manufacturing and Formulation Innovations	Development of modified-release formulations (e.g., Advagraf) to improve adherence and reduce side effects.	Expands therapeutic options and potential premium pricing.
Growing Transplant Procedures	Rising transplantation rates globally, especially in Asia-Pacific (due to increasing organ failure cases and expanding healthcare access).	Bolsters overall market size.
Monotherapy & Autoimmune Application Expansion	Research into tacrolimus for autoimmune diseases like atopic dermatitis and psoriasis, though off-label.	Potential future market expansion through clinical trials and approvals.

---

How Is the Global Market Structured?

Region	Market Share (2022 est.)	Key Players	Regulatory Context	Growth Outlook
North America	~45%	AbbVie, Astellas, Hikma	Mature, patent cliff passed, biosimilars active	Moderate growth, price pressures
Europe	~25%	Same as N. America, with regional manufacturers	Stringent regulations, biosimilar uptake	Steady growth
Asia-Pacific	~20%	Increasing presence of biosimilar producers	Growing transplantation infrastructure, expanding healthcare access	Rapid growth, double digits predicted (2023–2030)
Rest of World	~10%	Emerging markets	Varying regulatory frameworks	Growth driven by healthcare expansion

Source: Market Research Reports (e.g., Grand View Research, 2022[1])

---

What Are the Revenue and Sales Trends?

Key Metrics	2020	2021	2022	Projected 2025	Notes
Global Market Size	~$1.15 billion	~$1.25 billion	~$1.4 billion	~$1.8 billion	CAGR of approximately 10% (2022–2025)
Major Brand Sales	Prograf (AbbVie)	Declined post-patent expiration	Continued decline, stabilizing	Expected stabilization with biosymmetric competition	Abbott (now AbbVie) dominates original formulations
Biosimilar Market Share	N/A	Emerging	Significant (~25%) in mature markets	Expected to reach >50% in key markets	Biosimilars significantly impacting prices

---

What Challenges Could Impact the Market?

Challenge	Details	Potential Impact
Patent Expiry & Biosimilar Competition	Loss of exclusivity in propagated markets fosters price erosion.	Reduced profit margins and revenue decline for original manufacturers.
Pricing and Reimbursement Pressures	Cost-containment policies across healthcare payers prioritize biosimilars and generics.	Lower sales prices and increased market entry barriers.
Regulatory Barriers in Emerging Markets	Varying approval processes and quality standards.	Slowed market penetration and investment risks.
Clinical Safety and Side Effect Management	Tacrolimus’s side effects (nephrotoxicity, neurotoxicity) necessitate monitoring.	Limits expansion into off-label autoimmune or new indications.
Resistance and Variability in Bioavailability	Variability among generic/biosimilar formulations.	Prescriber and patient confidence issues, affecting market stability.

---

How Does the Financial Trajectory Look?

Financial Forecasts	2022	2025	2030	Assumptions & Drivers
Revenue Growth	~$1.4B	~$1.8B	~$2.4B	Continued transplant growth, biosimilar penetration, and emerging markets expansion
Market CAGR	~10%			Driven by Asia-Pacific expansion and increased transplantation rates
Profitability Trends	Stable margins pre-patent expiry	Declining margins due to biosimilar competition	Stabilization expected with market consolidation	Cost reductions in manufacturing, competitive pricing strategies

---

How Do Biosimilars Affect the Market?

Key Biosimilar Agents	Market Entry Year	Price Impact	Market Share Distribution	Major Generics/Biosimilars
Astellas’ ACS-14	2018	~20-30% price reduction	15-25% in mature regions	Approved in US and Japan
Hikma’s Tacrolimus	2019	Similar pricing	Gaining market share	Present in Europe and Middle East
Other Players	2020 onwards	Further erosion	Increasing adoption	Several regional entrants

Implication: The biosimilar launch accelerates price competition, erodes original brand revenues, yet enlarges the overall market by reducing treatment costs and increasing accessibility.

---

Comparing Tacrolimus to Alternatives: What Are the Competitive Advantages?

Agent	Brand	Mechanism	Formulations	Cost	Strengths	Weaknesses
Tacrolimus	Prograf (AbbVie), Advagraf, generic biosimilars	Calcineurin inhibitor	Immediate-release, extended-release	High (original); lower with biosimilars	Proven efficacy; flexible dosing	Side effects; monitoring required
Cyclosporine	Neoral, Sandimmune	Calcineurin inhibitor	Immediate and modified-release	Similar or lower	Well-established	Variety of side effects; drug interactions
Sirolimus	Rapamune	mTOR inhibitor	Oral	Higher than tacrolimus	Alternative in resistant cases	Different side effect profile
Mycophenolate Mofetil	CellCept	Antimetabolite	Oral, IV	Comparable	Often combined with tacrolimus	Gastrointestinal side effects

Summary: Tacrolimus maintains a leading position in transplant immunosuppression, but competition from other agents and biosimilars pressures market share and pricing.

---

Regulatory and Policy Landscape

Policy Area	Impact	Examples	Key Notes
Patent Laws & Data Exclusivity	Drive biosimilar entry timing	US (2017 patent expiry), EU	Patents significantly delay biosimilar market entry
Reimbursement Policies	Influence prescribing patterns	CMS, NICE	Favor biosimilars for cost savings
Regulatory Approvals	Agency standards essential	FDA, EMA, PMDA	Stringent biosimilar approval pathways facilitate entry
Trade Agreements	Affect market access	US-Mexico-Canada Agreement	Influence regional patent terms and biosimilar policies

---

Can Future Trends Alter the Market Trajectory?

Potential Trends	Description	Expected Outcomes
Personalized Immunosuppression	Biomarker-driven dosing	Better efficacy, reduced side effects
Innovative Formulations	Liposomal, nano-formulated tacrolimus	Improved safety profiles, adherence
New Indications	Autoimmune diseases	Expansion beyond transplantation
Pricing and Reimbursement Reforms	Cost-effective strategies	Increased biosimilar adoption, lower barriers

---

Key Takeaways

• Market Stability Rooted in Transplant Demand: Tacrolimus remains critical in transplant medicine, underpinning its sustained revenue.
• Patent Expiry Accelerates Biosimilar Competition: The expiration of original patents has led to aggressive biosimilar strategies, causing price erosion but expanding overall market volume.
• Regional Growth Disparities: Asia-Pacific presents the fastest growth prospects, driven by healthcare expansion and infrastructure development.
• Revenue Forecasts Will Be Influenced by Biosimilar Dynamics: The 10% CAGR through 2025 may moderate as biosimilars dominate the landscape.
• Future Potential Lies in New Formulations and Expanded Indications: Innovations and research into autoimmune applications could open additional revenue streams.

---

FAQs

1. How does biosimilar entry affect the profitability of original tacrolimus formulations?
Biosimilar entry significantly compresses profit margins due to pricing competition, necessitating strategic responses from original manufacturers, including formulation differentiation or value-added services.

2. Which regions are the primary growth drivers for tacrolimus?
Asia-Pacific leads growth projections owing to increasing transplantation procedures and expanding healthcare infrastructure, followed by steady growth in North America and Europe.

3. What are the main side effects influencing tacrolimus's market utilization?
Nephrotoxicity, neurotoxicity, hypertension, and increased risk of infections can limit broader application and necessitate close monitoring.

4. Are there oral formulations of tacrolimus with improved pharmacokinetics?
Yes. Modified-release formulations like Advagraf provide once-daily dosing, improving adherence. Research into novel delivery systems continues.

5. What future development strategies should stakeholders consider?
Focusing on biosimilar differentiation, expanding indications, advancing formulation technologies, and engaging in regional reimbursement negotiations are key strategies for sustaining or enhancing market share.

---

References

[1] Grand View Research. "Tacrolimus Market Size, Share & Trends Analysis Report," 2022.